| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | -0.061 | 0.05 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |